title: Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.
abstract: BACKGROUND
  Monocytes may have an important role in the resolution of venous thrombosis. Increased expression of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) is associated with an ingress of monocytes into the thrombus. This study was designed to evaluate the importance of these activators in thrombus resolution.
  
  
  RESULTS
  Inferior caval vein thrombosis was induced in cohorts of adult wild-type, uPA gene-knockout (uPA-/-), and tPA gene-knockout (tPA-/-) mice in a flow model. Thrombi were harvested from wild-type and uPA-/- mice (n=60 per group) between 1 and 60 days. Thrombi were also obtained from groups of wild-type and tPA-/- mice (n=24 per group) between 1 and 28 days. Thrombus size and macrophage content were measured by computer-assisted image analysis. Thrombus resolution was significantly impaired in the uPA-/- mice compared with wild-type controls (P<0.0001) but was unaffected in tPA-/- mice. Monocyte content in wild-type mice was highest at 14 days after thrombus induction and was approximately 4 times greater than in uPA-/- mice (P=0.0043). Thrombus size in uPA-/- mice transplanted with wild-type marrow (0.29+/-0.06 mm2) was significantly smaller than in uPA-/- mice given uPA-/- bone marrow (3.9+/-1.1 mm2) (P=0.0022). Donor bone marrow-derived cells expressing LacZ were present in the thrombus after transplantation.
  
  
  CONCLUSIONS
  The resolution of experimental venous thrombus is dependent on uPA but is unaffected by the absence of tPA. Absence of uPA is also associated with delayed monocyte recruitment into the thrombus. Transplanting wild-type bone marrow restores thrombus resolution in uPA-/- animals, suggesting an important role for bone marrow-derived cells in this process.
authors.affiliation: St Thomas' Hospital Campus, Kings College, London, UK.
authors.forename: I
authors.initials: I
authors.lastname: Singh
authors.forename: K G
authors.initials: KG
authors.lastname: Burnand
authors.forename: M
authors.initials: M
authors.lastname: Collins
authors.forename: A
authors.initials: A
authors.lastname: Luttun
authors.forename: D
authors.initials: D
authors.lastname: Collen
authors.forename: B
authors.initials: B
authors.lastname: Boelhouwer
authors.forename: A
authors.initials: A
authors.lastname: Smith
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation; D002452:Cell Count; D004195:Disease Models, Animal; D018450:Disease Progression; D005342:Fibrinolysis / Q000235:genetics; D018390:Gene Targeting; D017930:Genes, Reporter; D008264:Macrophages / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D009000:Monocytes / Q000473:pathology; D012075:Remission, Spontaneous; D010959:Tissue Plasminogen Activator / Q000172:deficiency / Q000235:genetics; D014568:Urokinase-Type Plasminogen Activator / Q000172:deficiency* / Q000235:genetics; D014654:Vascular Patency; D014682:Vena Cava, Inferior / Q000473:pathology; D020246:Venous Thrombosis / Q000235:genetics / Q000473:pathology* / Q000628:therapy*
chemical_list: D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator